The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases
Status:
Unknown status
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
This single-arm study will evaluate the resection rate of liver metastases in patients with
metastatic colorectal cancer and borderline unresectable liver metastases receiving treatment
with bevacizumab in combination with modified-FOLFOXIRI as first line treatment. Patients
will receive bevacizumab (5 mg/kg) plus modified-FOLFOXIRI (irinotecan 150 mg/m2, oxaliplatin
85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2400 mg/m2 as a 46-h continuous infusion)
every 14 days as neoadjuvant chemotherapy regimen. This study treatment will continue until
surgery, disease progression, unacceptable toxicity, or patient refusal.